<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05052892</url>
  </required_header>
  <id_info>
    <org_study_id>CHESS2105</org_study_id>
    <nct_id>NCT05052892</nct_id>
  </id_info>
  <brief_title>A Novel Spleen-dedicated Stiffness Measured by FibroScan to Evaluate Cirrhotic Portal Hypertension (CHESS2105)</brief_title>
  <official_title>A Novel Spleen-dedicated Stiffness Measured by FibroScan to Evaluate Cirrhotic Portal Hypertension (CHESS2105): A Prospective, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepatopancreatobiliary Surgery Institute of Gansu Province</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shulan (Hangzhou) Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third People's Hospital of Taiyuan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hepatopancreatobiliary Surgery Institute of Gansu Province</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Portal hypertension contributed to the main complications of liver cirrhosis. Currently,&#xD;
      hepatic venous pressure gradient (HVPG) was the reference standard for evaluating portal&#xD;
      pressure in patients with cirrhosis. However, the practice of HVPG is limited to require the&#xD;
      extensive experience and highly specialized centers. In recent years, non-invasive methods&#xD;
      were proposed to predict the degree of cirrhotic portal hypertension. Of them, liver&#xD;
      stiffness measured by FibroScan had shown good performance for predicting clinically&#xD;
      significant portal hypertension. However, the correlation between liver stiffness and HVPG&#xD;
      was poor when HVPG was more than 12mmHg. Since the spleen was stiffer than the liver, the&#xD;
      current vibration-controlled transient elastography examination is dedicated to the liver,&#xD;
      rather than the spleen. Very recently, a novel spleen-dedicated stiffness measured by&#xD;
      FibroScan was proposed. The prospective, multicenter study aims to evaluate the correlation&#xD;
      between SS (measured by the novel FibroScan) and HVPG, and further develop a novel model&#xD;
      based on SS for predicting the liver decompensation in patients with compenstaed cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Portal hypertension contributed to the main complications of liver cirrhosis. Currently,&#xD;
      hepatic venous pressure gradient (HVPG) was the reference standard for evaluating portal&#xD;
      pressure in patients with cirrhosis. However, the practice of HVPG is limited to require the&#xD;
      extensive experience and highly specialized centers. In recent years, non-invasive methods&#xD;
      were proposed to predict the degree of cirrhotic portal hypertension. Of them, liver&#xD;
      stiffness measured by FibroScan had shown good performance for predicting clinically&#xD;
      significant portal hypertension. However, the correlation between liver stiffness and HVPG&#xD;
      was poor when HVPG was more than 12mmHg. Since the spleen was stiffer than the liver, the&#xD;
      current vibration-controlled transient elastography examination is dedicated to the liver,&#xD;
      rather than the spleen. Very recently, a novel spleen-dedicated stiffness measured by&#xD;
      FibroScan was proposed. The prospective, multicenter study (CHESS2105 leaded by The First&#xD;
      Hospital of Lanzhou University and Shulan (Hangzhou) Hospital) aims to evaluate the&#xD;
      correlation between SS (measured by the novel FibroScan) and HVPG, and further develop a&#xD;
      novel model based on SS for predicting the liver decompensation in patients with compenstaed&#xD;
      cirrhosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 28, 2021</start_date>
  <completion_date type="Anticipated">September 27, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 27, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of a new model based on spleen stiffness (kPa) measured by transient elastography for diagnosing portal hypertension.</measure>
    <time_frame>1 years</time_frame>
    <description>In HVPG (mmHg) as reference method in evaluating portal pressure measured by intervention specialist , to develop a new model based on spleen stiffness (kPa) measured by transient elastography and evaluate the accuracy in diagnosing portal hypertension.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accuracy of model based on spleen stiffness (kPa) measured by transient elastography for predicting incidence of liver decompensation in patients with compenstaed cirrhosis</measure>
    <time_frame>3 years</time_frame>
    <description>To develop a novel model based on spleen stiffness (kPa) measured by transient elastography for predicting the incidence of liver decompensation in patients with compenstaed cirrhosis.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Training cohort</arm_group_label>
    <description>Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Validation cohort</arm_group_label>
    <description>Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Hepatic venous pressure gradient</intervention_name>
    <description>All patients underwent measurement of HVPG under local anesthesia.</description>
    <arm_group_label>Training cohort</arm_group_label>
    <arm_group_label>Validation cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients was fulfilled the diagnosis of cirrhosis based on radiological, histological&#xD;
        features of liver cirrhosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. age above or equal to 18-year-old&#xD;
&#xD;
          2. fulfilled diagnosis of cirrhosis based on radiological, histological features of liver&#xD;
             cirrhosis&#xD;
&#xD;
          3. signed informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Non-cirrhotic portal hypertension&#xD;
&#xD;
          2. Lactation or pregnancy&#xD;
&#xD;
          3. Suspicious or confirmed hepatocellular carcinoma&#xD;
&#xD;
          4. Asplenia or splenectomy&#xD;
&#xD;
          5. Incomplete clinical information&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lanjuan Li, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Shulan (Hangzhou) Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaolong Qi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LanZhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huadong Yan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shulan (Hangzhou) Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaolong Qi, MD</last_name>
    <phone>+8618588602600</phone>
    <email>qixiaolong@vip.163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruiling He, MD</last_name>
    <phone>+8618153674392</phone>
    <email>1037039754@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shulan (Hangzhou) Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Huadong Yan</last_name>
    </contact>
    <investigator>
      <last_name>Huadong Yan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liting Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Liting Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third People's Hospital of Taiyuan</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ying Guo</last_name>
    </contact>
    <investigator>
      <last_name>Ying Guo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Qi X, Berzigotti A, Cardenas A, Sarin SK. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):708-719. doi: 10.1016/S2468-1253(18)30232-2. Review.</citation>
    <PMID>30215362</PMID>
  </reference>
  <reference>
    <citation>de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3.</citation>
    <PMID>26047908</PMID>
  </reference>
  <reference>
    <citation>Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004 Feb;39(2):280-2. Review.</citation>
    <PMID>14767976</PMID>
  </reference>
  <reference>
    <citation>Bureau C, Metivier S, Peron JM, Selves J, Robic MA, Gourraud PA, Rouquet O, Dupuis E, Alric L, Vinel JP. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther. 2008 Jun;27(12):1261-8. doi: 10.1111/j.1365-2036.2008.03701.x. Epub 2008 Apr 4.</citation>
    <PMID>18397389</PMID>
  </reference>
  <reference>
    <citation>Colecchia A, Montrone L, Scaioli E, Bacchi-Reggiani ML, Colli A, Casazza G, Schiumerini R, Turco L, Di Biase AR, Mazzella G, Marzi L, Arena U, Pinzani M, Festi D. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology. 2012 Sep;143(3):646-654. doi: 10.1053/j.gastro.2012.05.035. Epub 2012 May 27.</citation>
    <PMID>22643348</PMID>
  </reference>
  <reference>
    <citation>Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, Petrarca A, Moscarella S, Belli G, Zignego AL, Marra F, Laffi G, Pinzani M. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology. 2007 May;45(5):1290-7.</citation>
    <PMID>17464971</PMID>
  </reference>
  <reference>
    <citation>Bastard C, Miette V, Calès P, Stefanescu H, Festi D, Sandrin L. A Novel FibroScan Examination Dedicated to Spleen Stiffness Measurement. Ultrasound Med Biol. 2018 Aug;44(8):1616-1626. doi: 10.1016/j.ultrasmedbio.2018.03.028. Epub 2018 May 3.</citation>
    <PMID>29731186</PMID>
  </reference>
  <reference>
    <citation>Stefanescu H, Marasco G, Calès P, Fraquelli M, Rosselli M, Ganne-Carriè N, de Ledinghen V, Ravaioli F, Colecchia A, Rusu C, Andreone P, Mazzella G, Festi D. A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices. Liver Int. 2020 Jan;40(1):175-185. doi: 10.1111/liv.14228. Epub 2019 Sep 11.</citation>
    <PMID>31444849</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hepatopancreatobiliary Surgery Institute of Gansu Province</investigator_affiliation>
    <investigator_full_name>Xiaolong Qi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <keyword>spleen stiffness</keyword>
  <keyword>portal hypertension</keyword>
  <keyword>hepatic venous pressure gradient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

